On multivariate analysis, factors significantly associated with lower survival in patients undergoing repeat TACE included an increase in number of tumour nodules at baseline (p = 0.02), a serum AFP ≥ 200 ng/ml (p = 0.001) and higher bilirubin following initial TACE (p = 0.007), and liver decompensation following repeat TACE (p = 0.001) (Table 4). This evidence concerns the gene AFP and neoplasm.